AQUA BIO TECHNOLOGY ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.2 NOK | +4.00% |
|
+4.21% | +52.05% |
| Apr. 25 | Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS. | CI |
| Apr. 23 | Norway-based Aqua Bio Technology Names New CFO | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 58.92 | 16.22 | 35.93 | 108.5 | 272.1 | 150.6 |
| Enterprise Value (EV) 1 | 38.43 | 12.95 | 29.06 | 103.9 | 265.8 | 165.7 |
| P/E ratio | -3.68 x | -0.89 x | -2.27 x | -6.5 x | -13.3 x | -7.88 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.96 x | 13.3 x | 27.7 x | 133 x | 138 x | 21 x |
| EV / Revenue | 3.89 x | 10.6 x | 22.4 x | 128 x | 135 x | 23.1 x |
| EV / EBITDA | -2.73 x | -0.74 x | -2.23 x | -6.5 x | -15.7 x | -10.9 x |
| EV / FCF | -3.42 x | -1.28 x | -2.53 x | -14.5 x | -14 x | -23.1 x |
| FCF Yield | -29.3% | -78% | -39.5% | -6.92% | -7.12% | -4.33% |
| Price to Book | 1.53 x | 0.81 x | 4.91 x | 13 x | 14.5 x | 81 x |
| Nbr of stocks (in thousands) | 6,931 | 6,931 | 15,355 | 18,387 | 20,611 | 20,661 |
| Reference price 2 | 8.500 | 2.340 | 2.340 | 5.900 | 13.20 | 7.290 |
| Announcement Date | 4/24/18 | 4/24/19 | 4/15/20 | 4/29/21 | 4/29/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 9.88 | 1.217 | 1.295 | 0.8126 | 1.976 | 7.161 |
| EBITDA 1 | -14.09 | -17.59 | -13 | -15.99 | -16.9 | -15.13 |
| EBIT 1 | -14.88 | -18.37 | -13.12 | -16.1 | -17.86 | -16.37 |
| Operating Margin | -150.58% | -1,509.04% | -1,013.33% | -1,981.81% | -903.89% | -228.56% |
| Earnings before Tax (EBT) 1 | -14.81 | -18.36 | -13.22 | -14.95 | -19.11 | -18.75 |
| Net income 1 | -16.06 | -18.36 | -13.22 | -14.7 | -19.11 | -18.74 |
| Net margin | -162.53% | -1,508.6% | -1,020.35% | -1,809.43% | -967.45% | -261.62% |
| EPS 2 | -2.313 | -2.644 | -1.030 | -0.9081 | -0.9947 | -0.9249 |
| Free Cash Flow 1 | -11.25 | -10.1 | -11.47 | -7.19 | -18.93 | -7.17 |
| FCF margin | -113.89% | -830.06% | -885.5% | -884.74% | -958.23% | -100.12% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/24/18 | 4/24/19 | 4/15/20 | 4/29/21 | 4/29/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 15 |
| Net Cash position 1 | 20.5 | 3.27 | 6.88 | 4.54 | 6.23 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.9942 x |
| Free Cash Flow 1 | -11.3 | -10.1 | -11.5 | -7.19 | -18.9 | -7.17 |
| ROE (net income / shareholders' equity) | -32% | -62.8% | -371% | -188% | -141% | -182% |
| ROA (Net income/ Total Assets) | -15.4% | -29% | -80.7% | -75.6% | -44.1% | -20.1% |
| Assets 1 | 104.1 | 63.29 | 16.37 | 19.45 | 43.38 | 93.07 |
| Book Value Per Share 2 | 5.560 | 2.870 | 0.4800 | 0.4500 | 0.9100 | 0.0900 |
| Cash Flow per Share 2 | 3.150 | 0.4700 | 0.4500 | 0.3000 | 0.6500 | 0.0900 |
| Capex 1 | 0.02 | 0.02 | 0.02 | 0.14 | - | - |
| Capex / Sales | 0.25% | 1.41% | 1.38% | 16.7% | - | - |
| Announcement Date | 4/24/18 | 4/24/19 | 4/15/20 | 4/29/21 | 4/29/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +52.05% | 27.58M | |
| +10.07% | 381B | |
| +14.18% | 74.67B | |
| -16.59% | 62.59B | |
| +0.82% | 52.86B | |
| -12.40% | 36.11B | |
| +3.54% | 33.57B | |
| +7.92% | 17.29B | |
| +6.30% | 14.75B | |
| -8.65% | 10.82B |
- Stock Market
- Equities
- ABT Stock
- Financials Aqua Bio Technology ASA
